The role of interleukin-17 in neurological disorders (2025)
- Authors:
- USP affiliated authors: ULRICH, ALEXANDER HENNING - IQ ; BRITTO, LUIZ ROBERTO GIORGETTI DE - ICB ; FERREIRA, ANA FLAVIA FERNANDES - ICB
- Unidades: IQ; ICB
- DOI: 10.1080/19768354.2025.2510994
- Subjects: FISIOLOGIA; INTERLEUCINAS; TRANSTORNOS MENTAIS; DOENÇAS NEURODEGENERATIVAS; CITOCINAS; DOENÇAS DO SISTEMA NERVOSO CENTRAL
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Animal Cells and Systems
- ISSN: 2151-2485
- Volume/Número/Paginação/Ano: v. 29, n. 1, p. 372-386, 2025
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
PARKA, Seung Eun et al. The role of interleukin-17 in neurological disorders. Animal Cells and Systems, v. 29, n. 1, p. 372-386, 2025Tradução . . Disponível em: https://doi.org/10.1080/19768354.2025.2510994. Acesso em: 12 fev. 2026. -
APA
Parka, S. E., Ferreira, A. F. F., Kwon, H., Yu, J., Diniz, L., Kim, E., et al. (2025). The role of interleukin-17 in neurological disorders. Animal Cells and Systems, 29( 1), 372-386. doi:10.1080/19768354.2025.2510994 -
NLM
Parka SE, Ferreira AFF, Kwon H, Yu J, Diniz L, Kim E, Ulrich H, Britto LRG de. The role of interleukin-17 in neurological disorders [Internet]. Animal Cells and Systems. 2025 ; 29( 1): 372-386.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1080/19768354.2025.2510994 -
Vancouver
Parka SE, Ferreira AFF, Kwon H, Yu J, Diniz L, Kim E, Ulrich H, Britto LRG de. The role of interleukin-17 in neurological disorders [Internet]. Animal Cells and Systems. 2025 ; 29( 1): 372-386.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1080/19768354.2025.2510994 - Neurodegeneration and glial morphological changes are both prevented by TRPM2 inhibition during the progression of a Parkinson's disease mouse model
- Deletion of the transient receptor potential Melastatin 2 gene mitigates the 6-hydroxydopamine-induced parkinson’s disease–like pathology
- Deletion of the transient receptor potential melastatin 2 gene mitigates the 6-hyydroxydopamine-induced Parkinson’s Disease–Like Pathology
- Inhibition of neuroinflammation by GIBH-130 (AD-16) reduces neurodegeneration, motor deficits, and proinflammatory cytokines in a hemiparkinsonian model
- The transient receptor potential melastatin 2: a new therapeutical target for Parkinson’s disease?
- Therapeutic potential of KATP channels in the attenuation of Parkinson's disease pathogenesis and progression: a review
- Inhibition of TRPM2 by AG490 is neuroprotective in a Parkinson’s Disease animal model
- Purinergic signaling in Parkinson’s disease
- Proliferation and differentiation of embryonic cells to neurons depende on purinergic receptor-induced calcium transients
- Carvacrol promotes neuroprotection in the mouse hemiparkinsonian model
Informações sobre o DOI: 10.1080/19768354.2025.2510994 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
